新华制药(000756.SZ)：醋酸泼尼松龙化学原料药上市申请获批准

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the marketing application of Acetate Prednisolone, which is primarily used for allergic and autoimmune inflammatory diseases [1] Group 1: Product Approval - The approval includes a notification for the marketing of Acetate Prednisolone as a chemical raw material drug [1] - The drug is indicated for various conditions including active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, nephrotic syndrome, thrombocytopenic purpura, granulocytopenia, adrenal cortical insufficiency, severe dermatitis, and acute leukemia [1] - It is also used in the comprehensive treatment of certain infections [1]